Table 3.
Rate ratios (RR) for developing breast cancer in relation to tertiles of plasma levels of inflammation biomarkers by menopausal status.
| Tertile I | Tertile II | Tertile III | P trend | Continuous (for 1 SD* increase) | |
|---|---|---|---|---|---|
| Postmenopausal women | |||||
| C-reactive protein | |||||
| Range, ng/ml | 0.005–2045.97 | 2047.44–5462.91 | 5469.28–164231.26 | ||
| Cases/Controls | 36/49 | 62/59 | 69/59 | ||
| RR1 (95% CI**) | 1 | 1.45 (0.80–2.64) | 1.77 (0.93–3.35) | 0.087 | 0.77 (0.51–1.15) |
| RR2 (95% CI) | 1 | 1.70 (0.89–3.23) | 2.42 (1.17–5.00) | 0.018 | 0.76 (0.52–1.12) |
| TNF-α | |||||
| Range, pg/ml | 0.009–0.6 | 0.605–1.63 | 1.64–110.51 | ||
| Cases/Controls | 42/42 | 48/51 | 77/74 | ||
| RR1 (95% CI) | 1 | 0.89 (0.43–1.84) | 0.92 (0.44–1.92) | 0.869 | 1.13 (0.90–1.41) |
| RR2 (95% CI) | 1 | 0.85 (0.40–1.81) | 0.86 (0.39–1.89) | 0.769 | 1.12 (0.89–1.41) |
| Interleukin-6 | |||||
| Range, pg/ml | 0.06–1.64 | 1.65–3.39 | 3.41–81.97 | ||
| Cases/Controls | 25/26 | 62/63 | 80/78 | ||
| RR1 (95% CI) | 1 | 1.02 (0.45–2.29) | 1.19 (0.49–2.88) | 0.611 | 1.07 (0.89–1.28) |
| RR2 (95% CI) | 1 | 1.24 (0.52–3.00) | 1.53 (0.59–3.96) | 0.345 | 1.09 (0.90–1.31) |
| Leptin | |||||
| Range, pg/ml | 222.82–4662.34 | 4672.62–8946.89 | 8949.08–26775.92 | ||
| Cases/Controls | 38/57 | 67/51 | 62/59 | ||
| RR1 (95% CI) | 1 | 1.84 (1.01–3.37) | 1.89 (0.92–3.85) | 0.092 | 1.33 (0.97–1.84) |
| RR2 (95% CI) | 1 | 1.69 (0.89–3.19) | 1.74 (0.83–3.63) | 0.164 | 1.30 (0.94–1.81) |
| Adiponectin | |||||
| Range, pg/ml | 976575.38–6567600 | 6590400–10776000 | 10778000–60520000 | ||
| Cases/Controls | 59/39 | 55/62 | 53/66 | ||
| RR1 (95% CI) | 1 | 0.49 (0.26–0.91 | 0.39 (0.21–0.76) | 0.006 | 0.81 (0.63–1.04) |
| RR2 (95% CI) | 1 | 0.49 (0.25–0.95) | 0.37 (0.19–0.72) | 0.004 | 0.80 (0.62–1.04) |
| Premenopausal women | |||||
| C-reactive protein | |||||
| Range, ng/ml | 0.005–2045.97 | 2047.44–5462.91 | 5469.28–164231.26 | ||
| Cases/Controls | 82/66 | 47/58 | 51/56 | ||
| RR1 (95% CI) | 1 | 0.68 (0.42–1.09) | 0.72 (0.40–1.29) | 0.171 | 0.94 (0.77–1.15) |
| RR2 (95% CI) | 1 | 0.68 (0.41–1.14) | 0.74 (0.40–1.37) | 0.253 | 0.94 (0.76–1.16) |
| TNF-α | |||||
| Range, pg/ml | 0.009–0.6 | 0.605–1.63 | 1.64–110.51 | ||
| Cases/Controls | 72/74 | 40/63 | 68/43 | ||
| RR1 (95% CI) | 1 | 0.76 (0.36–1.62) | 2.07 (0.94–4.57) | 0.016 | 1.78 (0.89–3.55) |
| RR2 (95% CI) | 1 | 0.80 (0.36–1.76) | 2.15 (0.95–4.86) | 0.017 | 1.81 (0.91–3.61) |
| Interleukin-6 | |||||
| Range, pg/ml | 0.06–1.64 | 1.65–3.39 | 3.41–81.97 | ||
| Cases/Controls | 82/88 | 52/53 | 46/39 | ||
| RR1 (95% CI) | 1 | 1.19 (0.65–2.18) | 1.65 (0.76–3.59) | 0.212 | 1.49 (0.96–2.31) |
| RR2 (95% CI) | 1 | 1.25 (0.67–2.33) | 1.89 (0.83–4.28) | 0.136 | 1.58 (1.02–2.46) |
| Leptin | |||||
| Range, pg/ml | 222.82–4662.34 | 4672.62–8946.89 | 8949.08–26775.92 | ||
| Cases/Controls | 87/59 | 43/65 | 50/56 | ||
| RR1 (95% CI) | 1 | 0.34 (0.18–0.64) | 0.42 (0.21–0.84) | 0.011 | 0.68 (0.47–0.94) |
| RR2 (95% CI) | 1 | 0.32 (0.16–0.64) | 0.43 (0.20–0.89) | 0.025 | 0.71 (0.50–0.99) |
| Adiponectin | |||||
| Range, pg/ml | 976575.38–6567600 | 6590400–10776000 | 10778000–60520000 | ||
| Cases/Controls | 65/78 | 69/54 | 46/48 | ||
| RR1 (95% CI) | 1 | 1.56 (0.94–2.61) | 1.09 (0.61–1.94) | 0.527 | 1.02 (0.78–1.35) |
| RR2 (95% CI) | 1 | 1.66 (0.97–2.85) | 1.11 (0.61–2.03) | 0.486 | 1.05 (0.79–1.40) |
*Standard deviation; **Confidence interval.
1Adjusted for age and BMI.
2Further adjusted for family history of breast cancer, age at menarche, parity, oral contraceptive use, smoking status, education, and alcohol consumption.